[HTML][HTML] Neuroinflammation in response to intracerebral injections of different HMGB1 redox isoforms

H Aucott, J Lundberg, H Salo, L Klevenvall… - Journal of innate …, 2018 - karger.com
H Aucott, J Lundberg, H Salo, L Klevenvall, P Damberg, L Ottosson, U Andersson, S Holmin…
Journal of innate immunity, 2018karger.com
Background: Neuroinflammation triggered by infection or trauma is the cause of central
nervous system dysfunction. High-mobility group box 1 protein (HMGB1), released from
stressed and dying brain cells, is a potent neuroinflammatory mediator. The proinflammatory
functions of HMGB1 are tightly regulated by post-translational redox modifications, and we
here investigated detailed neuroinflammatory responses induced by the individual redox
isoforms. Methods: Male Dark Agouti rats received a stereotactic injection of saline …
Background
Neuroinflammation triggered by infection or trauma is the cause of central nervous system dysfunction. High-mobility group box 1 protein (HMGB1), released from stressed and dying brain cells, is a potent neuroinflammatory mediator. The proinflammatory functions of HMGB1 are tightly regulated by post-translational redox modifications, and we here investigated detailed neuroinflammatory responses induced by the individual redox isoforms.
Methods
Male Dark Agouti rats received a stereotactic injection of saline, lipopolysaccharide, disulfide HMGB1, or fully reduced HMGB1, and were accessed for blood-brain barrier modifications using magnetic resonance imaging (MRI) and inflammatory responses by immunohistochemistry.
Results and Conclusions
Significant blood-brain barrier disruption appeared 24 h after injection of lipopolysaccharide, disulfide HMGB1, or fully reduced HMGB1 compared to controls, as assessed in post-gadolinium T1-weighted MRI images and confirmed by increased uptake of FITC-conjugated dextran. Immunohistochemistry revealed that both HMGB1 isoforms also induced a local production of IL-1β. Additionally, disulfide HMGB1 increased major histocompatibility complex class II expression and apoptosis. Together, the results demonstrate that extracellular, cerebral HMGB1 causes significant blood-brain barrier disruption in a redox-independent manner and activates several components of neuroinflammation. Blocking HMGB1 might potentially improve clinical outcome in conditions such as stroke and traumatic brain injury.
Karger